Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosa Fonti

Showing results (31-40 of 51) with videos related to

Pageof 6
Sort By:
Annals of Nuclear Medicine|October 16, 2019
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancerSara Pellegrino, Rosa Fonti, Emanuela Mazziotti, et al.
Cancers|August 27, 2021
Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER-Mitochondria Interface in Oncogene-Driven NSCLCViviana De Rosa, Francesca Iommelli, Cristina Terlizzi, et al.
Cancers|July 14, 2023
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine NeoplasmsLeandra Piscopo, Emilia Zampella, Sara Pellegrino, et al.
The Journal of Clinical Endocrinology and Metabolism|February 9, 2013
Evidence of brown fat activity in constitutional leannessFabrizio Pasanisi, Leonardo Pace, Rosa Fonti, et al.
Annals of Nuclear Medicine|January 13, 2016
Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinomaSerena De Luca, Rosa Fonti, Luigi Camera, et al.
Diagnostics (Basel, Switzerland)|July 29, 2023
Heterogeneity of Glycolytic Phenotype Determined by <sup>18</sup>F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced Non-Small Cell Lung CancerSara Pellegrino, Rosa Fonti, Armin Hakkak Moghadam Torbati, et al.
Annals of Hematology|February 8, 2007
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosisLucio Catalano, Silvana Del Vecchio, Fara Petruzziello, et al.
Medicine|October 20, 2017
Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapyBarbara Salvatore, Michele Klain, Emanuele Nicolai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3Antonella Zannetti, Francesca Iommelli, Rosa Fonti, et al.
Clinical Endocrinology|September 27, 2012
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PETVincenzo Marotta, Valeria Ramundo, Luigi Camera, et al.
Pageof 6

Showing results (31-40 of 51) with videos related to

Sort By:
Pageof 6
Annals of Nuclear Medicine|October 16, 2019
Total metabolic tumor volume by 18F-FDG PET/CT for the prediction of outcome in patients with non-small cell lung cancerSara Pellegrino, Rosa Fonti, Emanuela Mazziotti, et al.
Cancers|August 27, 2021
Non-Canonical Role of PDK1 as a Negative Regulator of Apoptosis through Macromolecular Complexes Assembly at the ER-Mitochondria Interface in Oncogene-Driven NSCLCViviana De Rosa, Francesca Iommelli, Cristina Terlizzi, et al.
Cancers|July 14, 2023
Diagnosis, Management and Theragnostic Approach of Gastro-Entero-Pancreatic Neuroendocrine NeoplasmsLeandra Piscopo, Emilia Zampella, Sara Pellegrino, et al.
The Journal of Clinical Endocrinology and Metabolism|February 9, 2013
Evidence of brown fat activity in constitutional leannessFabrizio Pasanisi, Leonardo Pace, Rosa Fonti, et al.
Annals of Nuclear Medicine|January 13, 2016
Multimodal imaging with (18)F-FDG-PET/CT and (111)In-Octreotide SPECT in patients with metastatic medullary thyroid carcinomaSerena De Luca, Rosa Fonti, Luigi Camera, et al.
Diagnostics (Basel, Switzerland)|July 29, 2023
Heterogeneity of Glycolytic Phenotype Determined by <sup>18</sup>F-FDG PET/CT Using Coefficient of Variation in Patients with Advanced Non-Small Cell Lung CancerSara Pellegrino, Rosa Fonti, Armin Hakkak Moghadam Torbati, et al.
Annals of Hematology|February 8, 2007
Sestamibi and FDG-PET scans to support diagnosis of jaw osteonecrosisLucio Catalano, Silvana Del Vecchio, Fara Petruzziello, et al.
Medicine|October 20, 2017
Prognostic role of FDG PET/CT in patients with differentiated thyroid cancer treated with 131-iodine empiric therapyBarbara Salvatore, Michele Klain, Emanuele Nicolai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 14, 2008
Gefitinib induction of in vivo detectable signals by Bcl-2/Bcl-xL modulation of inositol trisphosphate receptor type 3Antonella Zannetti, Francesca Iommelli, Rosa Fonti, et al.
Clinical Endocrinology|September 27, 2012
Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PETVincenzo Marotta, Valeria Ramundo, Luigi Camera, et al.
Pageof 6